BBP-398 + osimertinib
Phase 1Terminated 1 views this week 0 watching💤 Quiet
Interest: 11/100
11
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout BBP-398 + osimertinib
BBP-398 + osimertinib is a phase 1 stage product being developed by LianBio for NSCLC. The current trial status is terminated. This product is registered under clinical trial identifier NCT06032936. Target conditions include NSCLC.
What happened to similar drugs?
7 of 20 similar drugs in NSCLC were approved
Approved (7) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
6
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06032936 | Phase 1 | Terminated |
Competing Products
20 competing products in NSCLC